Phase 1 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with one of the following cancer types that has spread or cannot be surgically removed: non-small cell lung cancer, head and neck squamous cell carcinoma (but not nasopharyngeal cancer), esophageal squamous cell carcinoma, triple negative breast cancer, pancreatic cancer, liver cancer (hepatocellular carcinoma), stomach cancer, or endometrial cancer — depending on which part of the trial is involved
- People whose cancer has come back, stopped responding to standard treatments, or where standard treatments are not suitable or have not been tolerated
- People who have previously had a test showing their cancer's level of a protein called PD-L1 (confirm with trial site for exact level required, as this varies by cancer type and trial part)
- People who are generally well enough to carry out daily activities with little or no limitation (this is measured using a standard scale called ECOG, with a score of 0 or 1)
- People who have at least one area of cancer that can be measured on a scan using standard criteria
Who may not be able to join:
- People who have had another type of cancer diagnosed within the past 3 years, or who still show signs of a previously diagnosed cancer
- People with currently active cancer that has spread to the brain (though people whose brain metastases were previously treated may still be considered, if they have been stable for at least 4 weeks, have no new or growing brain spots, and have not needed steroid medication for brain-related symptoms for at least 7 days before starting the trial)
- People whose cancer has spread to the lining surrounding the brain and spinal cord
- People who have recently received certain immunotherapy drugs that target PD-L1 (specifically within a timeframe of less than 5 half-lives of that drug)
- People who have previously been treated with a drug containing a substance called MMAE (monomethylauristatin E)
- People who already have moderate or severe nerve damage (called neuropathy, grade 2 or higher) before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with adverse events (AEs); Number of participants with laboratory abnormalities; Number of participants with dose-limiting toxicities (DLTs); Number of participants with DLTs by dose level
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.